newsfilter
← Latest News
GlobeNewswire·

Instil Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update

  • Instil Bio, Inc. reported its second quarter 2026 financial results & provided a corporate update on August 13, 2026.
  • The company is evaluating potential acquisitions, in-licensing, & related opportunities to access novel therapeutic candidates.
  • Instil held approximately $69.9 million in cash, cash equivalents, restricted cash, & marketable securities as of June 30, 2026, expected to fund operations beyond 2027.
  • In-process research & development expenses were nil for the three & six months ended June 30, 2026, down from $10.0 million in the same periods of 2025.
  • Research & development expenses totaled $0.3 million & $0.9 million for the three & six months ended June 30, 2026, respectively, compared to $6.7 million & $12.1 million in 2025.
  • General & administrative expenses were $5.1 million & $10.5 million for the three & six months ended June 30, 2026, compared to $6.2 million & $15.3 million in 2025.
  • Restructuring & impairment charges were $0.2 million & $1.2 million for the three & six months ended June 30, 2026, compared to $0.5 million & $16.6 million in 2025.
  • Net loss per share, basic & diluted, was $0.63 & $1.25 for the three & six months ended June 30, 2026, respectively, compared to $3.24 & $7.55 in 2025.
  • Non-GAAP net loss per share, basic & diluted, was $0.45 & $0.78 for the three & six months ended June 30, 2026, respectively, compared to $2.88 & $4.21 in 2025.
  • Non-GAAP financial measures exclude non-cash stock-based compensation expense & restructuring & impairment charges to provide an alternative view of operating performance.